The hedgehog signaling pathway plays an important role in vertebrate embryonic development, tissue homeostasis, and tumorigenesis. Constitutive activation of Hh signaling in various human tumors leads to GLI-mediated transcription and tumor progression. Based on the preliminary screening of a large library of known triterpenes that exhibited interesting Hh inhibitory activity, we designed and synthesized a new series of triterpenoid analogues containing aromatic heterocyclic substituents at position C-2 to enhance their interference with Hh signaling. In this study, we evaluated the effect of 15 synthesized triterpenoids on cell proliferation and Hh pathway activity in relevant cancer cell lines. Among these compounds, two derivatives, 11a and 11b, both featuring a furan ring at position C-2, demonstrated potent inhibitory effects on proliferation and induced cell death in nonsmall cell lung cancer (NSCLC) and prostate cancer cell lines exhibiting hyper-activated Hh signaling. Moreover, these compounds significantly reduced GLI-mediated transcription in cell-based reporter assays. Detailed immunoblot analyses revealed that compounds 11a and 11b decreased the expression of endogenous GLI1 protein and its target genes associated with tumor progression and proliferation, such as Cyclin D1, N-Myc, and Bcl-2, in A549 and DU-145 cancer cells. These findings suggest that the antiproliferative effects of 11a and 11b are mediated through inhibition of the Hh signaling pathway and are promising candidates for the development of new anticancer therapies targeting Hh-dependent tumors.

Department of Organic Chemistry Faculty of Science Palacký University Olomouc 17 listopadu 1192 12 Olomouc 771 46 Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Hněvotínská 1333 5 Olomouc 779 00 Czech Republic

Laboratory of Experimental Medicine Institute of Molecular and Translational Medicine Czech Advanced Technology and Research Institute Palacký University Olomouc Šlechtitelů 241 27 Olomouc Holice 783 71 Czech Republic

Laboratory of Medicinal and Organic Chemistry Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University Olomouc Hněvotínská 1333 5 Olomouc 779 00 Czech Republic

Zobrazit více v PubMed

Zhang J.; Liu Z.; Jia J. Mechanisms of Smoothened Regulation in Hedgehog Signaling. Cells 2021, 10 (8), 2138.10.3390/cells10082138. PubMed DOI PMC

Jing J.; Wu Z.; Wang J.; Luo G.; Lin H.; Fan Y.; Zhou C. Hedgehog Signaling in Tissue Homeostasis, Cancers, and Targeted Therapies. Signal Transduct. Target. Ther. 2023, 8 (1), 1–33. 10.1038/s41392-023-01559-5. PubMed DOI PMC

Jiang J. Hedgehog Signaling Mechanism and Role in Cancer. Semin. Cancer Biol. 2022, 85, 107–122. 10.1016/j.semcancer.2021.04.003. PubMed DOI PMC

Lum L.; Beachy P. A. The Hedgehog Response Network: Sensors, Switches, and Routers. Science 2004, 304 (5678), 1755–1759. 10.1126/science.1098020. PubMed DOI

Wicking C.; Smyth I.; Bale A. The Hedgehog Signalling Pathway in Tumorigenesis and Development. Oncogene 1999, 18 (55), 7844–7851. 10.1038/sj.onc.1203282. PubMed DOI

Avery J. T.; Zhang R.; Boohaker R. J. GLI1: A Therapeutic Target for Cancer. Front. Oncol. 2021, 11, 673154.10.3389/fonc.2021.673154. PubMed DOI PMC

Peer E.; Tesanovic S.; Aberger F. Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. Cancers 2019, 11 (4), 538.10.3390/cancers11040538. PubMed DOI PMC

Nguyen N. M.; Cho J. Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance. Int. J. Mol. Sci. 2022, 23 (3), 1733.10.3390/ijms23031733. PubMed DOI PMC

Coupland C. E.; Andrei S. A.; Ansell T. B.; Carrique L.; Kumar P.; Sefer L.; Schwab R. A.; Byrne E. F. X.; Pardon E.; Steyaert J.; et al. Structure, mechanism, and inhibition of Hedgehog acyltransferase. Mol. Cell 2021, 81 (24), 5025–5038.e10. 10.1016/j.molcel.2021.11.018. PubMed DOI PMC

Yauch R. L.; Dijkgraaf G. J. P.; Alicke B.; Januario T.; Ahn C. P.; Holcomb T.; Pujara K.; Stinson J.; Callahan C. A.; Tang T.; Bazan J. F.; Kan Z.; Seshagiri S.; Hann C. L.; Gould S. E.; Low J. A.; Rudin C. M.; de Sauvage F. J. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science 2009, 326 (5952), 572–574. 10.1126/science.1179386. PubMed DOI PMC

Chang A. L. S.; Oro A. E. Initial Assessment of Tumor Regrowth after Vismodegib in Advanced Basal Cell Carcinoma. Arch. Dermatol. 2012, 148 (11), 1324–1325. 10.1001/archdermatol.2012.2354. PubMed DOI PMC

Pedersen K. K.; Høyer-Hansen M. H.; Litman T.; Hædersdal M.; Olesen U. H. Topical Delivery of Hedgehog Inhibitors: Current Status and Perspectives. Int. J. Mol. Sci. 2022, 23 (22), 14191.10.3390/ijms232214191. PubMed DOI PMC

Banaszek N.; Kurpiewska D.; Kozak K.; Rutkowski P.; Sobczuk P. Hedgehog Pathway in Sarcoma: From Preclinical Mechanism to Clinical Application. J. Cancer Res. Clin. Oncol. 2023, 149 (19), 17635–17649. 10.1007/s00432-023-05441-3. PubMed DOI PMC

Dzubak P.; Hajduch M.; Vydra D.; Hustova A.; Kvasnica M.; Biedermann D.; Markova L.; Urban M.; Sarek J. Pharmacological Activities of Natural Triterpenoids and Their Therapeutic Implications. Nat. Prod. Rep. 2006, 23 (3), 394–411. 10.1039/b515312n. PubMed DOI

Pokorny J.; Borkova L.; Urban M. Click Reactions in Chemistry of Triterpenes - Advances Towards Development of Potential Therapeutics. Curr. Med. Chem. 2018, 25 (5), 636–658. 10.2174/0929867324666171009122612. PubMed DOI

Cichewicz R. H.; Kouzi S. A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 2004, 24 (1), 90–114. 10.1002/med.10053. PubMed DOI

Jiang W.; Li X.; Dong S.; Zhou W. Betulinic Acid in the Treatment of Tumour Diseases: Application and Research Progress. Biomed. Pharmacother. 2021, 142, 111990.10.1016/j.biopha.2021.111990. PubMed DOI

Hill R. A.; Connolly J. D. Triterpenoids. Nat. Prod. Rep. 2020, 37 (7), 962–998. 10.1039/C9NP00067D. PubMed DOI

Hill R. A.; Connolly J. D. Triterpenoids. Nat. Prod. Rep. 2017, 34 (1), 90–122. 10.1039/C6NP00094K. PubMed DOI

Qian K.; Kim S.-Y.; Hung H.-Y.; Huang L.; Chen C.-H.; Lee K.-H. New Betulinic Acid Derivatives as Potent Proteasome Inhibitors. Bioorg. Med. Chem. Lett. 2011, 21 (19), 5944–5947. 10.1016/j.bmcl.2011.07.072. PubMed DOI PMC

Kazakova A.; Frydrych I.; Jakubcová N.; Pokorný J.; Lišková B.; Gurská S.; Buriánová R.; Přibylka A.; Džubák P.; Hajdúch M.; Urban M. Triterpenoid Phthalimides as Selective Anti-Cancer Agents Targeting Mitochondrial Apoptosis. Eur. J. Med. Chem. 2025, 283, 117126.10.1016/j.ejmech.2024.117126. PubMed DOI

Jonnalagadda S. C.; Corsello M. A.; Sleet C. E. Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents. Anticancer Agents Med. Chem. 2013, 13 (10), 1477–1499. 10.2174/18715230113129990094. PubMed DOI

Borkova L.; Hodon J.; Urban M. Synthesis of Betulinic Acid Derivatives with Modified A-Rings and Their Application as Potential Drug Candidates. Asian J. Org. Chem. 2018, 7 (8), 1542–1560. 10.1002/ajoc.201800163. DOI

Eichenmüller M.; Hemmerlein B.; von Schweinitz D.; Kappler R. Betulinic Acid Induces Apoptosis and Inhibits Hedgehog Signalling in Rhabdomyosarcoma. Br. J. Cancer 2010, 103 (1), 43–51. 10.1038/sj.bjc.6605715. PubMed DOI PMC

Milan U.; Ivo F.; Lucie B.; Marián H.; Barbora V.. Triterpeny s inhibiční aktivitou na Hedgehog signální dráhu pro použití při léčbě nádorových onemocnění. CZ309885, STARFOS, 2023.

Rodríguez-Hernández D.; Demuner A. J.; Barbosa L. C. A.; Heller L.; Csuk R. Novel Hederagenin–Triazolyl Derivatives as Potential Anti-Cancer Agents. Eur. J. Med. Chem. 2016, 115, 257–267. 10.1016/j.ejmech.2016.03.018. PubMed DOI

Hodoň J.; Frydrych I.; Trhlíková Z.; Pokorný J.; Borková L.; Benická S.; Vlk M.; Lišková B.; Kubíčková A.; Medvedíková M.; Pisár M.; Šarek J.; Das V.; Ligasová A.; Koberna K.; Džubák P.; Hajdúch M.; Urban M. Triterpenoid Pyrazines and Pyridines – Synthesis, Cytotoxicity, Mechanism of Action, Preparation of Prodrugs. Eur. J. Med. Chem. 2022, 243, 114777.10.1016/j.ejmech.2022.114777. PubMed DOI

Kazakova A.; Frydrych I.; Jakubcová N.; Pokorný J.; Lišková B.; Gurská S.; Džubák P.; Hajdúch M.; Urban M. Novel Triterpenoid Pyrones, Phthalimides and Phthalates Are Selectively Cytotoxic in CCRF-CEM Cancer Cells – Synthesis, Potency, and Mitochondrial Mechanism of Action. Eur. J. Med. Chem. 2024, 269, 116336.10.1016/j.ejmech.2024.116336. PubMed DOI

Urban M.; Sarek J.; Klinot J.; Korinkova G.; Hajduch M. Synthesis of A-Seco Derivatives of Betulinic Acid with Cytotoxic Activity. J. Nat. Prod. 2004, 67 (7), 1100–1105. 10.1021/np049938m. PubMed DOI

Borková L.; Frydrych I.; Vránová B.; Jakubcová N.; Lišková B.; Gurská S.; Džubák P.; Pavliš P.; Hajdúch M.; Urban M. Lupane Derivatives Containing Various Aryl Substituents in the Position 3 Have Selective Cytostatic Effect in Leukemic Cancer Cells Including Resistant Phenotypes. Eur. J. Med. Chem. 2022, 244, 114850.10.1016/j.ejmech.2022.114850. PubMed DOI

Regueiro-Ren A.; Swidorski J. J.; Liu Z.; Chen Y.; Sin N.; Sit S.-Y.; Chen J.; Venables B. L.; Zhu J.; Nowicka-Sans B.; Protack T.; Lin Z.; Terry B.; Samanta H.; Zhang S.; Li Z.; Easter J.; Beno B. R.; Arora V.; Huang X. S.; Rahematpura S.; Parker D. D.; Haskell R.; Santone K. S.; Cockett M. I.; Krystal M.; Meanwell N. A.; Jenkins S.; Hanumegowda U.; Dicker I. B. Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)Ethyl)Amino)-5a,5b,8,8,11a-Pentamethyl-1-(Prop-1-En-2-Yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-Octadecahydro-1H-Cyclopenta[a]Chrysen-9-Yl)Benzoic Acid (GSK3532795, BMS-955176). J. Med. Chem. 2018, 61 (16), 7289–7313. 10.1021/acs.jmedchem.8b00854. PubMed DOI

Lin P.; He Y.; Chen G.; Ma H.; Zheng J.; Zhang Z.; Cao B.; Zhang H.; Zhang X.; Mao X. A Novel Hedgehog Inhibitor for the Treatment of Hematological Malignancies. Anticancer. Drugs 2018, 29 (10), 995–1003. 10.1097/CAD.0000000000000679. PubMed DOI

Lemos T.; Merchant A. The Hedgehog Pathway in Hematopoiesis and Hematological Malignancy. Front. Oncol. 2022, 12, 960943.10.3389/fonc.2022.960943. PubMed DOI PMC

Liu R.; Shi P.; Wang Z.; Yuan C.; Cui H. Molecular Mechanisms of MYCN Dysregulation in Cancers. Front. Oncol. 2021, 10, 625332.10.3389/fonc.2020.625332. PubMed DOI PMC

Yuan Z.; Goetz J. A.; Singh S.; Ogden S. K.; Petty W. J.; Black C. C.; Memoli V. A.; Dmitrovsky E.; Robbins D. J. Frequent Requirement of Hedgehog Signaling in Non-Small Cell Lung Carcinoma. Oncogene 2007, 26 (7), 1046–1055. 10.1038/sj.onc.1209860. PubMed DOI

Di L.; Kerns E. H.; Hong Y.; Chen H. Development and Application of High Throughput Plasma Stability Assay for Drug Discovery. Int. J. Pharm. 2005, 297 (1), 110–119. 10.1016/j.ijpharm.2005.03.022. PubMed DOI

Artursson P.; Palm K.; Luthman K. Caco-2 Monolayers in Experimental and Theoretical Predictions of Drug transport1PII of Original Article: S0169–409X(96)00415–2. The Article Was Originally Published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1. Adv. Drug Delivery Rev. 2001, 46 (1), 27–43. 10.1016/S0169-409X(00)00128-9. PubMed DOI

Irvine J. D.; Takahashi L.; Lockhart K.; Cheong J.; Tolan J. W.; Selick H. E.; Grove J. R. MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening. J. Pharm. Sci. 1999, 88 (1), 28–33. 10.1021/js9803205. PubMed DOI

Nassar A. F.Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability. In Drug Metabolism Handbook: Concepts and Applications; John Wiley & Sons, Ltd, 2008, pp. 253–268. DOI: 10.1002/9780470439265.ch10. DOI

Wohnsland F.; Faller B. High-Throughput Permeability pH Profile and High-Throughput Alkane/Water Log P with Artificial Membranes. J. Med. Chem. 2001, 44 (6), 923–930. 10.1021/jm001020e. PubMed DOI

Dehaen W.; Mashentseva A. A.; Seitembetov T. S. Allobetulin and Its Derivatives: Synthesis and Biological Activity. Molecules 2011, 16 (3), 2443–2466. 10.3390/molecules16032443. PubMed DOI PMC

Korovin A. V.; Tkachev A. V. Synthesis of Quinoxalines Fused with Triterpenes, Ursolic Acid and Betulin Derivatives. Russ. Chem. Bull. 2001, 50 (2), 304–310. 10.1023/A:1009598805986. DOI

Vlk M.; Urban M.; Elbert T.; Sarek J. Synthesis of Selectively Deuterated and Tritiated Lupane Derivatives with Cytotoxic Activity. J. Radioanal. Nucl. Chem. 2013, 298 (2), 1149–1157. 10.1007/s10967-013-2533-8. DOI